Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALTO-101 · 1 trial · 2 indications
Theta band activity after 5 and 10 days of dosing of ALTO-101T compared to placebo.
| Arm | Type | Description |
|---|---|---|
| ALTO-101 | EXPERIMENTAL | 10 days administration of ALTO-101T transdermal delivery system |
| Placebo | PLACEBO_COMPARATOR | 10 days administration of placebo transdermal delivery system |
| Name | Type | Description |
|---|---|---|
| ALTO-101 | DRUG | ALTO-101 patches |
| ALTO-101 Transdermal Delivery System | DEVICE | ALTO-101 transdermal delivery system |
| Placebo | DRUG | Inactive placebo patches |
| Placebo Transdermal Delivery System | DEVICE | Placebo transdermal delivery system |
Inclusion Criteria: * Schizophrenia diagnosis for at least one year * Cognitive impairment * Stable doses of 1-2 antipsychotic medication(s) for at least 8 weeks at Visit 2 * Positive and Negative Syndrome Scale (PANSS) score: items P1, P3-P6 ≤ 5 and item P2 and P7 ≤ 4 during screening * Have a bod...
Top 15 of 16 competitors
ALTO-101 is an investigational small molecule being developed for the treatment of cognitive impairment associated with schizophrenia. It is currently in Phase 2 clinical development and has not been approved by the FDA.
ALTO-101 targets PDE4, an enzyme involved in intracellular signaling pathways. By inhibiting PDE4, the drug is designed to address cognitive deficits in schizophrenia. It is being studied in patients with schizophrenia and cognitive impairment.
ALTO-101 is being developed by Alto Neuroscience, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ANRO. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
ALTO-101 is in Phase 2 clinical development. It is an investigational drug that has not yet received FDA approval. The drug has been granted Fast Track designation by the FDA for its intended use in schizophrenia.
ALTO-101 is being studied in a Phase 2 clinical trial registered as NCT06502964, titled 'Study of ALTO-101 in Patients With Schizophrenia.' This randomized, double-blind, placebo-controlled trial is recruiting 82 participants in the United States.
No alternative names for ALTO-101 have been reported. It is identified solely by its developmental code name ALTO-101 and is being investigated by Alto Neuroscience for cognitive impairment in schizophrenia.